![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 24-Oct-2012[ | E-mail |
Share ] Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Results of PARTNER Cohort B trial presented at TCT 2012
MIAMI, FL OCTOBER 24, 2012 A study found that transcatheter aortic valve replacement (TAVR) yielded lower mortality rates after three years compared with medical therapy in patients deemed to be ineligible for conventional aortic valve surgery. Results of the PARTNER Cohort B trial were presented today at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.
TAVR is the recommended treatment for patients with severe aortic stenosis who are not suitable candidates for surgery. Outcomes beyond two years in such patients have not yet been extensively studied.
Inoperable patients with severe symptomatic aortic stenosis (AS) were randomly assigned to transfemoral TAVR or to standard therapy (which often included balloon aortic valvuloplasty) in the PARTNER trial. Data on three-year outcomes were analyzed according to intention to treat (ITT).
A total of 358 patients underwent randomization at 21 centers. The Kaplan Meier estimated rates of death at three years were 54.1 percent in the TAVR group and 80.9 percent in the standard-therapy group (P
"After three years of follow-up, the benefits of TAVR were sustained as measured by all cause mortality, cardiovascular mortality, repeat hospitalization, and functional status," said one of the investigators, E. Murat Tuzcu, MD. Dr. Tuzcu is Professor of Medicine and Vice-Chairman of the Department of Cardiology in the Sydell and Arnold Heart & Vascular Institute at the Cleveland Clinic.
"Three-year data continue to support the role of TAVR as the standard-of-care for symptomatic patients with aortic stenosis who are not surgical candidates," said Dr. Tuzcu.
The results of PARTNER Cohort B Three Year will be presented on Wednesday October 24 at 12:17 PM EST in the Main Arena (Hall D) of the Miami Beach Convention Center.
###
The trial was funded by Edwards Lifesciences. Dr. Tuzcu reported no financial conflicts of interest.
About CRF
The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in interventional cardiovascular medicine.
Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of the Cardiovascular Research Foundation. TCT gathers leading medical researchers and clinicians from around the world to present and discuss the latest developments in the field.
For more information, visit www.crf.org.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 24-Oct-2012[ | E-mail |
Share ] Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Results of PARTNER Cohort B trial presented at TCT 2012
MIAMI, FL OCTOBER 24, 2012 A study found that transcatheter aortic valve replacement (TAVR) yielded lower mortality rates after three years compared with medical therapy in patients deemed to be ineligible for conventional aortic valve surgery. Results of the PARTNER Cohort B trial were presented today at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.
TAVR is the recommended treatment for patients with severe aortic stenosis who are not suitable candidates for surgery. Outcomes beyond two years in such patients have not yet been extensively studied.
Inoperable patients with severe symptomatic aortic stenosis (AS) were randomly assigned to transfemoral TAVR or to standard therapy (which often included balloon aortic valvuloplasty) in the PARTNER trial. Data on three-year outcomes were analyzed according to intention to treat (ITT).
A total of 358 patients underwent randomization at 21 centers. The Kaplan Meier estimated rates of death at three years were 54.1 percent in the TAVR group and 80.9 percent in the standard-therapy group (P
"After three years of follow-up, the benefits of TAVR were sustained as measured by all cause mortality, cardiovascular mortality, repeat hospitalization, and functional status," said one of the investigators, E. Murat Tuzcu, MD. Dr. Tuzcu is Professor of Medicine and Vice-Chairman of the Department of Cardiology in the Sydell and Arnold Heart & Vascular Institute at the Cleveland Clinic.
"Three-year data continue to support the role of TAVR as the standard-of-care for symptomatic patients with aortic stenosis who are not surgical candidates," said Dr. Tuzcu.
The results of PARTNER Cohort B Three Year will be presented on Wednesday October 24 at 12:17 PM EST in the Main Arena (Hall D) of the Miami Beach Convention Center.
###
The trial was funded by Edwards Lifesciences. Dr. Tuzcu reported no financial conflicts of interest.
About CRF
The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in interventional cardiovascular medicine.
Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of the Cardiovascular Research Foundation. TCT gathers leading medical researchers and clinicians from around the world to present and discuss the latest developments in the field.
For more information, visit www.crf.org.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2012-10/crf-scb102412.php
deep impact usssa baseball alex o loughlin the godfather cape breton bowling green marysville
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.